Ulisse Biomed Past Earnings Performance
Past criteria checks 0/6
Ulisse Biomed's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been declining at an average rate of 54.1% per year.
Key information
-8.5%
Earnings growth rate
-116.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -54.1% |
| Return on equity | -33.2% |
| Net Margin | -1,843.3% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ulisse Biomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -1 | 0 | 0 |
| 31 Dec 22 | 0 | -1 | 0 | 0 |
| 30 Sep 22 | 0 | -1 | 0 | 0 |
| 30 Jun 22 | 0 | -1 | 0 | 0 |
| 31 Mar 22 | 0 | -1 | 0 | 0 |
| 31 Dec 21 | 0 | -1 | 0 | 0 |
| 30 Sep 21 | 0 | 0 | 0 | 0 |
| 30 Jun 21 | 1 | 0 | 0 | 0 |
| 31 Mar 21 | 1 | 0 | 0 | 0 |
| 31 Dec 20 | 1 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 31 Dec 18 | 0 | -2 | 1 | 0 |
Quality Earnings: 8XX is currently unprofitable.
Growing Profit Margin: 8XX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8XX is unprofitable, and losses have increased over the past 5 years at a rate of 8.5% per year.
Accelerating Growth: Unable to compare 8XX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8XX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: 8XX has a negative Return on Equity (-33.2%), as it is currently unprofitable.